Concluding that every breast and ovarian patient with a BRCA1 and BRCA2 mutation detected after diagnosis is a missed opportunity to prevent a cancer, Professor King declared that based on a UK cost-effectiveness analysis of population-based screening, costs would be absolutely acceptable, considering that market forces are driving down test expenses. Here, BRCA2 is linked to cancer.